본문으로 건너뛰기
← 뒤로

Senescent hepatic stellate cells drive inflammation and disease progression in MASH (Review).

Experimental and therapeutic medicine 2026 Vol.31(4) p. 95

Han Z, She Y, Wu D, Zhang N, Liu Z, Wang Z, Zhou X, Li S

📝 환자 설명용 한 줄

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by steatosis, inflammation, hepatocellular injury and fibrosis, with the capacity to progress to cirrhosis and hepatocellular c

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Han Z, She Y, et al. (2026). Senescent hepatic stellate cells drive inflammation and disease progression in MASH (Review).. Experimental and therapeutic medicine, 31(4), 95. https://doi.org/10.3892/etm.2026.13090
MLA Han Z, et al.. "Senescent hepatic stellate cells drive inflammation and disease progression in MASH (Review).." Experimental and therapeutic medicine, vol. 31, no. 4, 2026, pp. 95.
PMID 41694108

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by steatosis, inflammation, hepatocellular injury and fibrosis, with the capacity to progress to cirrhosis and hepatocellular carcinoma. Recent evidence highlights cellular senescence, particularly in hepatic stellate cells (HSCs) as a key regulator of MASH pathogenesis. Senescent HSCs exhibit a context-dependent duality whereby, while transient senescence limits fibrosis through cell-cycle arrest, matrix degradation and enhanced immune clearance, persistent senescence under chronic metabolic and inflammatory stress drives disease progression. Through an expanded senescence-associated secretory phenotype (SASP), senescent HSCs exacerbate inflammation, promote extracellular matrix deposition, alter immune responses and facilitate malignant transformation. The present review summarizes the molecular mechanisms inducing HSC senescence, including lipotoxicity, oxidative stress, DNA damage, mitochondrial dysfunction and impaired autophagy. The mechanisms by which SASP factors mediate crosstalk between senescent HSCs and other cell types are discussed, including hepatocytes, macrophages, T cells and natural killer cells, collectively altering the inflammatory and fibrotic microenvironment of MASH. Finally, emerging therapeutic strategies targeting cellular senescence are highlighted, such as senolytics, senomorphics and biomarker-guided interventions, which may offer promising avenues for modifying the course of MASH and preventing disease progression.

같은 제1저자의 인용 많은 논문 (5)